c-Myc
Myc
The transcription factor c-Myc is a member of the basic helix-loop-helix leucinezipper (bHLHZip) protein family. The target genes of the c-MYC protein participate in different cellular functions, including cell cycle, survival, protein synthesis, cell adhesion, and micro-RNA expression. c-Myc is also one of the four factors used in reprogramming somatic cells to induce pluripotent stem (iPS) cells and is implicated in maintaining cancer stem-like cells (CSCs). Most biological functions of c-Myc require heterodimerization with its activation partner Max.
c-Myc is also part of a dynamic network whose members interact selectively with one another and with various transcriptional coregulators and histone-modifying enzymes. Deregulated expression of c-MYC caused by gene amplification, retroviral insertion, or chromosomal translocation is associated with tumorigenesis. c-Myc has been identified as a highly promising target for cancer therapy.
All Product Categories
-
c-Myc Related Products (290)
Related Products (290)
-
Antibodies (12)
-
Idarubicin hydrochloride (Standard)
0 ImagesCat. No.: HY-17381RCAS No.: 57852-57-0Synonyms: 4-Demethoxydaunorubicin hydrochloride (Standard)Idarubicin (hydrochloride) (Standard) is the analytical standard of Idarubicin (hydrochloride). This product is intended for research and analytical applications. Idarubicin hydrochloride is an anthracycline antileukemic agent. It inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin hydrochloride inhibits the growth of bacteria and yeasts.
-
PF-4942847
0 ImagesCat. No.: HY-108336CAS No.: 1046859-34-0PF-4942847 is an orally active HSP90 inhibitor with an IC50 of approximately 50 nM. PF-4942847 induces apoptosis in osteosarcoma cells, increases the proportion of cells in the sub-G1 phase and PARP cleavage, reduces the expression of Akt, Erk, MYC, c-MET and STAT-3, and regulates HSP expression. PF-4942847 can be used in studies related to osteosarcoma and HSP90.
-
10074-G5 (Standard)
0 ImagesCat. No.: HY-100996RCAS No.: 413611-93-5
-
NUCC-0201642
0 ImagesCat. No.: HY-180454CAS No.: 2289691-70-7
-
IZCZ-3 (Standard)
0 ImagesCat. No.: HY-111411RCAS No.: 2223019-53-0
-
(-)-CMLD010509
0 ImagesCat. No.: HY-119271ACAS No.: 2240186-24-5Synonyms: (-)-SDS-1-021(-)-CMLD010509 ((-)-SDS-1-021) is an isomer of CMLD010509 (SDS-1-021) (HY-119271). CMLD010509 (SDS-1-021) is a highly specific inhibitor of the oncogenic translation program supporting multiple myeloma (MM)-including key oncoproteins such as MYC, MDM2, CCND1, MAF, and MCL-1. CMLD010509 (SDS-1-021) shows an IC50 below 10 nM for most MM cell lines and induces apoptosis. CMLD010509 (SDS-1-021) is a potent and selective translation inhibitor through an eIF4E phosphorylation-independent mechanism.
-
Antiproliferative agent-75
0 ImagesCat. No.: HY-181473CAS No.: 3102226-11-6Antiproliferative agent-75, Pyrrole (HY-Y0807) derivative, is an antiproliferative agent with an IC50 value of 0.06 μM against Myc-driven human B-cells. Antiproliferative agent-75 can be used for the development of pyrrole-based Myc inhibitor.
-
DMBA (Standard)
0 ImagesSynonyms: 7,12-DMBA (Standard); 7,12-Dimethylbenzanthracene (Standard)DMBA has carcinogenic activity as a polycyclic aromatic hydrocarbon (PAH). DMBA is used to induce tumor formation in various rodent models.
-
Ertabresib (Standard)
0 ImagesCat. No.: HY-111485RCAS No.: 1820889-23-3Synonyms: INCB-057643 (Standard)Ertabresib (Standard) (INCB-057643 (Standard)) is the analytical standard of Ertabresib (HY-111485). This product is intended for research and analytical applications. Ertabresib (INCB-057643) is an orally active BET protein inhibitor. Ertabresib blocks gene transcription by targeting the BET protein family, induces cell cycle arrest and apoptosis by downregulating proto-oncogenes such as c-MYC, and additionally reduces the expression of FOXP3 and PD-L1 to improve the immune microenvironment. It also exerts synergistic effects and overcomes drug resistance when combined with chemotherapy and XPO1 inhibitors. Ertabresib can be used in research related to high-grade B-cell lymphoma with MYC and BCL2 rearrangements, pancreatic cancer, pancreatitis, and metastatic castration-resistant prostate cancer.
-
Nuvisertib hydrochloride
0 ImagesCat. No.: HY-101126ACAS No.: 1418143-09-5Synonyms: TP-3654 hydrochlorideNuvisertib hydrochloride (TP-3654 hydrochloride) is an orally active second-generation pan-PIM kinase inhibitor with Ki values of 5 nM, 239 nM, and 42 nM against PIM-1, PIM-2, and PIM-3, respectively. Nuvisertib hydrochloride inhibits JAK-independent inflammatory and survival signaling pathways, reduces the production of proinflammatory cytokines, restores apoptotic sensitivity, inhibits mTORC1, MYC, and TGF-β signaling pathways, and decreases the expression of fibrosis markers. Nuvisertib hydrochloride selectively impairs the transport function of ABCG2, resensitizes multidrug-resistant cancer cells to cytotoxic drugs, and overcomes JAK2 inhibitor resistance. Nuvisertib hydrochloride can be used in research related to myelofibrosis, renal cell carcinoma, multidrug-resistant cancer, advanced solid tumors, urothelial carcinoma, and prostate adenocarcinoma.
